NCT05820074 Investigating Neural Biomarkers for Gait in Parkinson's Patients
| NCT ID | NCT05820074 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Swiss Federal Institute of Technology |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-04-13 |
| Primary Completion | 2025-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-04-13 with a primary completion date of 2025-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study's main goal is to learn more about the neural mechanisms during movement in Parkinson's disease. Furthermore, it aims to inspire personalised treatment options. Participants will undergo a protocol that involves walking and gait-related motor tasks, such as seated stepping. During the protocol, brain activity will be recorded.
Eligibility Criteria
Inclusion Criteria: All participants * must have given informed consent as documented by signature * agree to comply with the study procedures Healthy control group * no neurological, orthopedic, or rheumatologic disease history * no identified sensory impairment. * no epilepsy and self-diagnosed acute or chronic psychiatric disorders Parkinson's Patients * non-tremor dominant idiopathic PD patients * presence of postural instability (UPDRS \>1 for postural instability \[17\]), gait disturbance, and absence of other causes of reduced balance * Implanted with Percept™ PC neurostimulator * Able to be in the stimulation OFF Exclusion Criteria: * Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \< 20 * History of physical or neurological condition that interferes with study procedures * Social and/or personal circumstances interfering with the ability to come to the session
Contact & Investigator
Olivier Lambercy, PhD
PRINCIPAL INVESTIGATOR
RELab, ETH Zürich
Frequently Asked Questions
Who can join the NCT05820074 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05820074 currently recruiting?
Yes, NCT05820074 is actively recruiting participants. Contact the research team at lena.salzmann@hest.ethz.ch for enrollment information.
Where is the NCT05820074 trial being conducted?
This trial is being conducted at Vitznau, Switzerland.
Who is sponsoring the NCT05820074 clinical trial?
NCT05820074 is sponsored by Swiss Federal Institute of Technology. The principal investigator is Olivier Lambercy, PhD at RELab, ETH Zürich. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.